Novartis Oral MS Drug Meets Endpoints in Two Phase 3 Trials, Stock Rises Over 4%
nashnova research
Novartis's oral drug remibrutinib met primary endpoints in two Phase III trials, beating Sanofi's Aubagio on both relapse rate and inflammatory brain lesions; the stock rose 4.5% intraday, and analysts project peak sales above $10 billion across indications.
What exactly did these two trials prove?
The trials enrolled roughly 2,000 patients with relapsing multiple sclerosis — the most common form of MS, where neurological symptoms flare up repeatedly.
Both trials hit their primary endpoints: remibrutinib cut the annualized relapse rate and reduced inflammatory brain lesions versus Aubagio, with a clean safety profile.
This means → the drug didn't just match the comparator — it beat it on both hard measures, what Bank of America calls a "best-case" outcome.
How big could this drug get for Novartis?
Bank of America estimates peak annual sales of $3 billion for remibrutinib in MS alone.
The drug is already approved in the US and EU under the brand name "Rhapsido" for chronic spontaneous urticaria — a skin condition with recurring hives. Adding other indications could push total peak sales past $10 billion.
In plain terms = MS is the biggest piece of the puzzle, but not the only one — the approved skin indication plus future expansions add up to a $10-billion-plus revenue profile.
What about the competition — why did Roche fall?
Roche has its own oral MS candidate, fenebrutinib, targeting the same drug class. On the day Novartis released its data, Roche shares dropped 1.8%.
JPMorgan analysts cautioned that a full comparison requires detailed data still to come.
This reflects the market's snap judgment: Novartis delivered a "best-case" scorecard first, tilting the competitive balance its way for now — but the final verdict is not in.
Why does Novartis need this result so badly?
Several blockbusters, including the heart-failure drug Entresto, lost patent protection last year. Revenue dipped before rebounding last quarter on strength in other core products.
Novartis already has Kesimpta as a top-selling MS therapy; approval of remibrutinib would deepen its moat in the space.
This means → this is not just good news for one drug — it is a critical step in Novartis's effort to refill the pipeline behind a patent cliff. The company expects to release several more key data readouts in coming months; delivering consistently is the market's core test of its medium-term growth story.
市场有风险，内容仅供研究参考，不构成投资建议。